Sign In
Buy KYMR
$98.25
-1.20 (-1.21%)
At Close: Jun 23, 2026
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Thursday, 05'th Nov 2020
Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi
WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein
U.S. IPO Week Ahead: The IPO Market Braces For A September SNOWstorm In A 12-IPO Week
11:07am, Sunday, 13'th Sep 2020
The post-Labor Day IPO frenzy is here as 12 IPOs plan to raise $6.8 billion in the coming week, led by cloud data unicorn Snowflake.
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
06:48am, Sunday, 23'rd Aug 2020
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. The week's eight SPAC IPOs raised $3.3 billion.
